Member Info for chester18

The 9.29p trades on Aquis are buys based on that is what I paid. I just can’t resist a bargain 👍

Asx newsfeed article from 5 mins ago following on from Alien Metals RNS earlier today.

https://themarketonline.com.au/west-coast-tracks-high-spiking-silver-prices-with-high-intensity-exploration-2025-09-02/

Cannot read it but who are Scannell ?

I presume it’s a typo as you have posted it on here.

Can we take such an article seriously when the name of the company is incorrectly spelt in the title.

What is needed is a vaccine that targets the Spike proteins and the Nucleus of the virus. Something that creates memory ’T’ Cells that continues to protect against minor mutations in the Spike proteins.

I’m sure there was some research and development of such a vaccine, just can’t bring it to mind 🤔

Well we know that news is landing in September and because it’s Modi1 combined with two checkpoints for the very first time, this news has the potential to stir up the market.

As before I have my fingers, toes and eye’s crossed in hopeful anticipation.

The clock is ticking ……. ⏰

Not that many RNS’s and also not as many Conferences ‘at the moment’.

As each week passes more patients are reaching their first scan dates and the clinical data mounts up.

Three fair sized purchases 250k, 250k and 175k in the last week. While Scancell is being shunned by the general investor these trades are moping up all the loose shares.

Martin Diggle recently buying 10,000,000 shares suggests to me that the trials are doing well as far as he’s concerned,

The next clinical trial RNS promised Q3 so very soon.

It's not my head that needs examining its Gods Clock that is ticking a bit faster now than when I bought my first 250k shares, back in 2013.

I was totally committed to the Scancell story and enjoyed all the early enthusiasm as we learnt more and more about how ModiTope worked. We have been in 'very nearly land' for longer that I ever anticipated. The continiual mantra from each presentation that Shareholder Value is a priority is wearing a bit thin.

Lets just call it what it is 'Investor Fatigue' and being very blunt the company from early 2024 set up expectations that so far have not been met.

If the retail market ( AIM ) has no say in the value of Scancells estate then there can be no complaints when a derisory offer is made by a potential buyer of the company. AIM has proved time and time again that it reacts to hype over actual value.

If none of the items I listed raise the SP as news arrives when will Scancell ever achieve 'Investor Value'.

Modi1 plus checkpoints in Renal Cell Carcinoma has every chance to perform as well or potentially better than the checkpoints helped SCIB1 in the SCOPE trial.

Moditope has to show synergy with double checkpoints.

Agreed EE but we need the AIM market to start seeing Scancell as a success story.

10p per share is ‘derisory -4p’ according to Vulpes.

News in the pipeline :

Modi1 Renal Cell update

Modi1 Neoadjuvant ( 15 patients Mono and 15 patients plus single checkpoint )

Modi1 Head and Neck plus single checkpoint.

GenMab - actual intention to start a Ph1 clinical trial.

GlyMab Theraputics Ltd. Initial moves to populate that company.

SC134 pre-clinical readiness and development of potential trial approvals.

Not to mention the SCOPE Trial ……

So many attempts on goal that 25p or 30p would not be unrealistic. AIM market does not value any of the above and is full of 10% traders.

So what do we need from the Modi1 update to at least cause some long term interest in Scancell’s stock?

Given that there will only be a maximum of 10 to 12 patients that have reached their 13 week scans, what clinical numbers would we need to successfully move the SP northward ?

Come on EE it’s a punchy title ……. Would certainly get people talking …… 😂😂

The Modify update that will arrive in the next 5 weeks could have a huge impact on our Conference attendance success. Whether it’s the numbers of people wanting to have meetings with Scancell or the industry level of those people.

By adding Modi1 to the Standard of Care ‘Double Checkpoints’ in Renal Cell Carcinoma we may see major improvements to patient outcomes. Just as we saw in the SCOPE trial.

The update is the first big test for ModiTope using a double checkpoints to unlock the tumour micro environment.

I would be very happy if the title of the RNS is ‘Modi1 plus 2x Checkpoints Devastates RCC Tumours’.

Thank you Marcus for your reply and I totally agree with C11 and TF.

Scancell has a very strong, experience and knowledgeable team when dealing with bio-technology, clinical trials and approval bodies. The reason I raised the issue 'being on point' with the SCOPE Reg Trial is just to highlight the fact that the FDA is evolving under these new Trump restrictions.

We do not know and can not know for certain what the approval criteria will be in 2028.

So Scancell will have to be watching and listening all through the trial to ensure the goalposts are not moving away from the stated aims of our trial.

Replimune and Krystal Biotech obviously started their trials based on what was acceptable and now is not.

Scancell don't need me to email them but I thought it was a good discussion point to make.

Hi Marcus

I’ve just read that article about Replimune’s dressing down by the FDA. It shows how the FDA is evolving and the different standards that are now being demanded for new treatments.

Krystal Biotech using a very similar modality also using Opdivo saw that there was little hope of success in continuing their trial.

Scancell will need to ensure that the SCOPE Registration Trial is on point.

One other thing to factor is the purchases of Mr Martin Diggle. He’s a non-exec but still cannot be possession of information that is materially relevant to the share price.

The ‘Director Dealing’ RNS was on the 8th August so to be outside of a closed period I presume the Modi RNS will need to be at least one month later. So after the 9th September?

Yes, that very flimsy prediction now looks like a proper dud.

Thinking about how Scancell will want to present that update, they will probably take as much time out of Q3 as possible to present as much data as possible.

We know that under this new CEO if he says Q3 it will be Q3.

So new prediction time ……

Still going for a Thursday but now the 25th September.

Or possibly tomorrow 🤣🤣🤣

Currently the SP rates all of Scancells prospect's at roughly 10% success.

With this amount of potential all queueing up for their time to shine there will be a tipping point.

That moment could come with the next Modi update or the GenMab deal or the Scope updated around Christmas.

But it will happen 👍

I’ve just looked at the posts over there.

Just trash talk, back and forth.

It’s just like fleas arguing over who owns the dog.

In fact it’s quite sad 🫣

Hi Marcus134

Modi1 as a mono therapy did amazingly well in the early stages of the ModiFy trial.

Modi1 plus a single Checkpoint showed the potential improvements that may be achieved with a ModiTope plus a Checkpoint Combo.

Based on how SCIB1 has been able to infiltrate tumours with the aid of double checkpoints I’m very confident that the results in the Renal Cell Carcinoma cohort will mean another superb improvement for those patients taking part.

ModiTope is an amazing discovery in the battle to understand how best to unlock the immune system and defeat late stage cancer tumours.

🤞🤞🤞🤞

Immunobody……….

Immunonody is a an allergy to Noddy and Big Ears…. 🤣🤣🤣🤣🤣